Effect of rifampicin pretreatment on the oral bioavailability of domperidone in healthy human volunteers

References

1. Reynolds JC. Prokinetic agents: a key in the future of gastroenterology. Gastroenterol Clin North Am 1989;18:437–57.10.1016/S0889-8553(21)00686-5Search in Google Scholar

2. Heykants J, Hendriks R, Meuldermans W, Michiels M, Scheygrond H, Reyntjens H. On the pharmacokinetics of domperidone in animals and man. IV. The pharmacokinetics of intravenous domperidone and its bioavailability in man following intramuscular, oral and rectal administration. Eur J Drug Metab Ph 1981;6:61–70.10.1007/BF03189516Search in Google Scholar PubMed

3. Ward BA, Morocho A, Kandil A, Galinsky RE, Flockhart DA, Desta Z. Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 2004;58:277–87.10.1111/j.1365-2125.2004.02156.xSearch in Google Scholar PubMed PubMed Central

4. Meuldermans W, Hurkmans R, Swysen E, Hendrickx J, Michiels M, Lauwers W, et al. On the pharmacokinetics of domperidone in animals and man III. Comparative study on the excretion and metabolism of domperidone in rats, dogs and man. Eur J Drug Metab Ph 1981;6:49–60.10.1007/BF03189515Search in Google Scholar PubMed

5. Tsujikawa K, Dan Y, Nogawa K, Sato H, Yamada Y, Murakami H, et al. Potentiation of domperidone-induced catalepsy by a P-glycoprotein inhibitor, cyclosporin A. Biopharm Drug Dispos 2003;24:105–14.10.1002/bdd.343Search in Google Scholar PubMed

6. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517–24.10.1172/JCI118699Search in Google Scholar PubMed PubMed Central

7. Vesely JJ, Pien FD, Pien BC. Rifampicin, a useful drug for nonmycobacterial infections. Pharmcotherapy 1998;18:345–57.10.1002/j.1875-9114.1998.tb03861.xSearch in Google Scholar

8. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992;22:47–65.10.2165/00003088-199222010-00005Search in Google Scholar PubMed

9. Heimark LD, Gibaldi M, Trager WF, O’Reilly RA, Goulart DA. The mechanism of the warfarin-rifampicin drug interaction in humans. Clin Pharmacol Ther 1987;42:388–94.10.1038/clpt.1987.168Search in Google Scholar PubMed

10. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther 2000;68:401–11.10.1067/mcp.2000.110561Search in Google Scholar PubMed

11. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147–53.10.1172/JCI6663Search in Google Scholar PubMed PubMed Central

12. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Bioavailability of cyclosporin with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453–7.10.1038/clpt.1992.171Search in Google Scholar PubMed

13. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction, Clin Pharmacol Ther 2000;68:345–55.10.1067/mcp.2000.109797Search in Google Scholar PubMed

14. Jayasagar G, Krishna Kumar M, Chandrasekhar K, Madhusudan Rao Y. Influence of rifampicin pretreatment on the pharmacokinetics of celecoxib in healthy male volunteers. Drug Metab Drug Interact 2003:19:287–95.10.1515/DMDI.2003.19.4.287Search in Google Scholar

15. Yumoto R, Murakami T, Nakamoto Y, Hasegawa R, Nagai J, Takano M. Transport of rhodamine 123, a P-glycoprotein substrate, across rat intestine and Caco-2 cell monolayer in the presence of cytochrome P-450 3A-related compounds. J Pharmaol Exp Ther 1999;289:149–55.10.1016/S0022-3565(24)38117-0Search in Google Scholar